Navigation Links
Medivation Reports Fourth Quarter and Year-End 2008 Financial Results and Provides Corporate Update
Date:3/16/2009

torical fact may be deemed to be forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause Medivation's actual results to differ significantly from those projected, including, without limitation, risks related to progress, timing and results of Medivation's clinical trials, difficulties or delays in obtaining regulatory approval, enrollment of patients in Medivation's clinical trials, partnering of Medivation's product candidates, manufacturing of Medivation's product candidates, competition with Medivation's product candidates should they receive marketing approval, the adequacy of Medivation's financial resources, unanticipated expenditures or liabilities, intellectual property matters, and other risks detailed in Medivation's filings with the Securities and Exchange Commission, including its annual report on Form 10-K for the year ended December 31, 2008 filed today with the SEC. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. Medivation disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release.

                       ~financial statements to follow~

                                      MEDIVATION, INC.
                           CONSOLIDATED STATEMENTS OF OPERATIONS
                           (In thousands, except per share data)

                                                Year ended December 31,
                                             2008         2007         2006

    Collaboration revenue                  $12,578         $-           $-

    Operating expenses:
       Research and development             54,895       23,399       11,825
       Selling, general and administrative  21,865       10,364        4,321

              Total operating expenses      76,760       33,763       16,146


'/>"/>
SOURCE Medivation, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Medivation Announces New Positive Efficacy Data From Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients
2. Medivation Presents New Data on Dimebons Novel Mechanism of Action
3. Medivation Announces Participation in RBC Capital Markets 2008 Healthcare Conference
4. Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update
5. Medivation Announces Third Quarter 2008 Teleconference and Webcast on November 10, 2008
6. Medivation Announces Expiration of Hart-Scott-Rodino Waiting Period for Collaboration With Pfizer
7. Medivation Announces Presentation of 24-Week Clinical Data of MDV3100 in Castration-Resistant Prostate Cancer Patients
8. Medivation Receives Corporate Achievement Award From Huntingtons Disease Society of America
9. Medivation to Host Conference Call at 8:30 a.m. Eastern Time Tomorrow to Discuss Partnering Plans for Dimebon
10. Medivation Announces Participation in Upcoming Conferences
11. Medivation Reports Second Quarter 2008 Financial Results and Provides Corporate Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... 2015 The National Necrotizing Fasciitis Foundation ... saved by doctors at Vanderbilt University Hospital in ... Pharmaceuticals and Dr. John Crew , director of ... Medical Center in Daly City, CA. ... approach, pioneered by Dr. Crew, that had previously saved ...
(Date:8/27/2015)... DIEGO , Aug. 27, 2015 HUYA ... annual meeting of the Japan Society of HTLV-1, held ... Institute Auditorium. The purpose of the Society is to ... as the development of medical technology and research related ... and welfare. "HUYA is proud to support ...
(Date:8/27/2015)... ... 27, 2015 , ... METTLER TOLEDO's web-based EasyFinder™ ... choices to a manageable shortlist of bench and floor scales and terminals. Specifying ... best with the customer’s industry and application. , Side-by-side product comparisons and ...
(Date:8/26/2015)... ... August 26, 2015 , ... MediVet ... a second US laboratory is to open in Manhattan, Kansas in early October, ... and long-term growth of research and development through collaboration with researchers from Kansas ...
Breaking Biology Technology:Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 2Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 3HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 2HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 3HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 4METTLER TOLEDO Updates Online Scale Selection Tool 2MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 2MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 3
... -- WuXi PharmaTech (NYSE:,WX), China,s premier provider ... Governor Deval L. Patrick of the Commonwealth ... China,Partnership Official Delegation, paid a visit to ... (Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO ), ...
... Systems, a leader in the field of,sleep diagnostic ... an,exclusive agreement with the Beth Israel Deaconess Medical ... Coupling (CPC) technology,developed by Drs. Robert Thomas, Ary ... technology represents a breakthrough in how sleep can ...
... Results to be presented at San Antonio Breast ... Agendia BV, world,leader in the rapidly evolving field ... consortium has demonstrated the,prognostic power of its MammaPrint(R) ... positive lymph nodes. The data show that,MammaPrint(R) can ...
Cached Biology Technology:Massachusetts Governor Deval L. Patrick Pays Visit to WuXi PharmaTech 2Massachusetts Governor Deval L. Patrick Pays Visit to WuXi PharmaTech 3Embla Systems in Collaboration with Beth Israel Deaconess Medical Center to Develop Cardio-Pulmonary Coupling Technology 2MammaPrint(R) Breast Cancer Test Validated in Lymph Node-Positive Breast Cancer Patients 2MammaPrint(R) Breast Cancer Test Validated in Lymph Node-Positive Breast Cancer Patients 3
(Date:8/5/2015)... August 5, 2015 According to ... Management Market by Software, Services, Vertical (BFSI, Airport, IT & ... - Global Forecast to 2020", published by MarketsandMarkets, defines ... globally into various segments. The global PIAM Market is ... $546.2 Million by 2019, at a CAGR of 14.9 ...
(Date:8/5/2015)... VIEW, Calif. , Aug. 5, 2015 ... exhibits continuous growth in applications, penetration into newer sectors, ... after year. The global biosensors space has seen the ... exited the market so far. (Photo - ... Frost & Sullivan, Analysis of the Global Biosensors ...
(Date:8/4/2015)... 2015  AMRI (NASDAQ: AMRI ) today reported financial and ... Highlights: , Second quarter contract revenue of ... , Adjusted contract margins of 26 % ... a $0.05 decrease in EPS from royalties in the current quarter ... "We are very pleased to present another strong financial ...
Breaking Biology News(10 mins):Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24
... therapy has been identified by Monash University scientists investigating ... involved in cancer development. , A team led by ... has identified two proteins that are involved in stopping ... is essential if cancer cells are to proliferate. , ...
... the Nov. 24 issue of Science provide further support for ... new evidence that adult precursor cells from the spleen can ... and 2003, researchers at Massachusetts General Hospital (MGH) demonstrated the ... in diabetic mice. Three studies from other institutions published ...
... dolphin drive hunts begin in the Japanese villages of Taiji ... aquarium professionals has launched a campaign to end the practices ... Japan to put an end to the hunts. The "Act ... Emory University, and the World Association of Zoos and Aquariums ...
Cached Biology News:New target for cancer therapy identified 2New data from NIH lab confirms protocol to reverse type 1 diabetes in mice 2Renewed dolphin slaughter prompts new campaign 2Renewed dolphin slaughter prompts new campaign 3
... Cell Lines ,High Quality, Functionally-Validated, Ion Channel ... known for having a critical role in ... a key function in pain, CNS and ... have been investigated in therapeutic areas, such ...
... Cell Lines ,High Quality, Functionally-Validated, Ion Channel ... known for having a critical role in ... a key function in pain, CNS and ... have been investigated in therapeutic areas, such ...
Mouse monoclonal antibody raised against a partial recombinant CHD8. NCBI Entrez Gene ID = CHD8...
Mouse monoclonal antibody raised against a partial recombinant PASK. NCBI Entrez Gene ID = PASK...
Biology Products: